Doxorubicin + Cyclophosphamide + Paclitaxel (AC-T Chemotherapy Regimen)
Treatment for Breast Cancer
Typical Dosage: Doxorubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 (every 2-3 weeks); Paclitaxel 80 mg/m2 weekly or 175 mg/m2 every 3 weeks
Effectiveness
80%
Safety Score
25%
Clinical Trials
21
Participants
150K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Doxorubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 (every 2-3 weeks); Paclitaxel 80 mg/m2 weekly or 175 mg/m2 every 3 weeks
Time to Effect
Weeks
Treatment Duration
3-6 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$8,000
Side Effect Mgmt:$5,000
Total Annual:$28,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$40,000
Cost per Remission
$70,000
Doxorubicin + Cyclophosphamide + Paclitaxel (AC-T Chemotherapy Regimen) Outcomes
for Breast Cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+70%
Remission Rate
+40%
Common Side Effects
Nausea and vomiting
+80%
Hair loss
+100%
Fatigue
+90%
Neutropenia/Infection
+40%
Cardiotoxicity (Doxorubicin)
+5%
Peripheral neuropathy (Paclitaxel)
+60%
Sources:
Active Clinical Trials
5 active trials recruiting for Doxorubicin + Cyclophosphamide + Paclitaxel (AC-T Chemotherapy Regimen) in Breast Cancer
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
NCT02957968ACTIVE NOT RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Edgewood, United States +3 more
Started: Jan 24, 2017
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
NCT04872985ACTIVE NOT RECRUITINGPHASE2
140 participants
INTERVENTIONAL
Guangzhou, China
Started: Apr 20, 2021
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
NCT03283384ACTIVE NOT RECRUITINGPHASE2
100 participants
INTERVENTIONAL
's-Hertogenbosch, Netherlands +28 more
Started: Jun 15, 2019
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
NCT04373031ACTIVE NOT RECRUITINGPHASE2
12 participants
INTERVENTIONAL
Portland, United States
Started: Dec 30, 2020
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
NCT06404463NOT YET RECRUITINGPHASE2
76 participants
INTERVENTIONAL
Started: May 6, 2024
Completed Clinical Trials
8 completed trials for Doxorubicin + Cyclophosphamide + Paclitaxel (AC-T Chemotherapy Regimen) in Breast Cancer
Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)
NCT04170465COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Beheira, Egypt
Started: Oct 29, 2019
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
NCT00093795COMPLETEDPHASE3
4.89K participants
INTERVENTIONAL
Birmingham, United States +11 more
Started: Oct 1, 2004
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT01501487COMPLETEDPHASE4
226 participants
INTERVENTIONAL
Mobile, United States +8 more
Started: Oct 1, 2011
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
NCT00546156COMPLETEDPHASE2
104 participants
INTERVENTIONAL
Boston, United States +3 more
Started: Oct 1, 2007
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
NCT00014222COMPLETEDPHASE3
2.1K participants
INTERVENTIONAL
Fort Smith, United States +77 more
Started: Dec 4, 2000
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00455533COMPLETEDPHASE2
384 participants
INTERVENTIONAL
Palm Springs, United States +48 more
Started: Oct 1, 2007
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
NCT02018458COMPLETEDPHASE1, PHASE2
10 participants
INTERVENTIONAL
Dallas, United States
Started: May 1, 2014
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
NCT00499083COMPLETEDPHASE2
17 participants
INTERVENTIONAL
Tampa, United States +1 more
Started: May 1, 2006
Showing 20 of 21 total trials